



Kynetyka Technologies Pty Ltd
ABN 88 614 880 956
65 Hardys Road Underdale SA 5032
www.kynetyka.com.au

MEDIA RELEASE

Kynetyka and Flinders Factory of the Future advance Deep Vein Thrombosis detection with new DVTest® sensor technology

13 August 2026; Adelaide Australia: Kynetyka Technologies Pty Ltd (“Kynetyka”), an Adelaide-based medical device company, is pleased to announce that a new prototype wireless DVTest® sensor has been designed, developed and delivered by a team of engineers at the Flinders University Factory of the Future, based at Tonsley Innovation District.

The project marks an important milestone in the development of Kynetyka's DVTest® technology, which is designed to provide a rapid, non-invasive method of assessing patients for Deep Vein Thrombosis (DVT), a potentially life-threatening condition that can lead to pulmonary embolism if left undetected.

The new DVTest® sensor is designed to effectively capture the movement data in a patient's leg, and transmit that data wirelessly to the proprietary DVTest® software for analysis. The sensor is a critical component of the DVTest® system, accurately recording the biomechanical signals that are used by the software to assess the presence of DVT.

Craig Newton, CEO of Kynetyka, said the successful development of a purpose-built DVTest® sensor is a major milestone for the company and an important step towards improving DVT detection and healthcare delivery

“It enables us to optimise the quality and performance of a critical component of the DVTest® platform while strengthening our pathway to commercialisation. We are proud to have partnered with Flinders Factory of the Future on a project that advances our goal of delivering a faster, simpler and more accessible approach to DVT detection.”

In designing and developing the new DVTest® sensor, the Factory of the Future engineers leveraged their expertise in physiological sensing, wearable technologies, data capture and signal analysis. The team designed and developed the sensor's electronics, firmware and wireless features to deliver a compact, purpose-built device tailored specifically to the needs of the DVTest® platform supporting the rapid assessment of DVT.

Professor Karen Reynolds, Director of the Factory of the Future, said the project demonstrates how advanced manufacturing and engineering expertise can be applied to address important healthcare challenges.

“We worked closely with Kynetyka to develop a purpose-built sensor that supports the DVTect® platform's assessment of DVT. It also highlights the depth of expertise available in South Australia to support the development and commercialisation of innovative medical technologies.”

This project received grant funding from the Australian Government.

For further information, contact Kynetyka:

Craig Newton, CEO and MD
cnewton@kynetyka.com.au
Phone: +61 (0) 434 674 256

Kynetyka Technologies Pty Ltd

Kynetyka Technologies Pty Ltd (Kynetyka) is an Australian medical device company, headquartered in Adelaide. The company is developing and commercialising DVTect®, a unique, patented, point-of-care software and device to detect Deep Vein Thrombosis.

Kynetyka is led by a team of respected clinicians and professionals. The executive team has collectively over 120 years' global experience in medical, pharmaceutical, and technology development sectors.

Deep Vein Thrombosis (DVT)

DVT is a blood clot in a vein, often in the leg. The clot can dislodge, travel to the lungs and lead to life-threatening pulmonary embolism and sometimes death. The USA Centre for Disease Control estimates there are up to 900,000 affected and 100,000 deaths in the USA per annum. There are approximately 8,000 deaths in Australia every year.

Currently, DVT testing is performed using doppler ultrasound, but 75% to 80% of ultrasounds for suspected DVT do not find a DVT in the patient. Due to delays for results from both ultrasound and blood tests, patient may receive anticoagulants out of caution. These drugs may result in bleeding and complications.

DVTect® technology

When a patient has a deep vein thrombosis (DVT) in the leg, there is a demonstrable change in the calf muscles. The DVTect® test starts with a sensor attached to a leg, which is lightly tapped to cause movement in the muscle. The resulting 3D waveform data is recorded and transmitted to the DVTect® software, where it is analysed for the presence of DVT with test results presented on a smart device, computer, or medical records.

DVTect® is faster and easier to use than all ultrasound devices and is designed to be used at the hospital bedside and in the community. DVTect® reduces needless ultrasounds, deaths from pulmonary embolisms, and overuse of anticoagulants and represents an estimated healthcare cost saving of over \$4 billion in the USA and Australia.

Flinders Factory of the Future

The Factory of the Future is a Flinders University initiative based at the Tonsley Innovation District in Adelaide. It helps Australian companies accelerate innovation and commercialisation through access to specialist expertise in advanced manufacturing, product development, digital technologies, engineering and industry-focused research. The Factory of the Future works collaboratively with businesses to develop new products, improve manufacturing capability and support growth in high-value industries, including medical technologies.